Antares Pharma (NASDAQ: ATRS) reported Q1 EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $11.1 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.